<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36675440</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12020511</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long-term coronavirus disease 2019 (long COVID) is associated with physio-somatic (chronic fatigue syndrome and somatic symptoms) and affective (depression and anxiety) symptoms. The severity of the long COVID physio-affective phenome is largely predicted by increased peak body temperature (BT) and lowered oxygen saturation (SpO2) during the acute infectious phase. This study aims to delineate whether the association of BT and SpO2 during the acute phase and the long COVID physio-affective phenome is mediated by neurotoxicity (NT) resulting from activated immune-inflammatory and oxidative stress pathways.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 86 patients with long COVID (3-4 months after the acute phase) and 39 healthy controls and assessed serum C-reactive protein (CRP), caspase 1, interleukin (IL) 1&#x3b2;, IL-18, IL-10, myeloperoxidase (MPO), advanced oxidation protein products (AOPPs), total antioxidant capacity (TAC), and calcium (Ca), as well as peak BT and SpO2 during the acute phase.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cluster analysis revealed that a significant part (34.9%) of long COVID patients (n = 30) show a highly elevated NT index as computed based on IL-1&#x3b2;, IL-18, caspase 1, CRP, MPO, and AOPPs. Partial least squares analysis showed that 61.6% of the variance in the physio-affective phenome of long COVID could be explained by the NT index, lowered Ca, and peak BT/SpO2 in the acute phase and prior vaccinations with AstraZeneca or Pfizer. The most important predictors of the physio-affective phenome are Ca, CRP, IL-1&#x3b2;, AOPPs, and MPO.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The infection-immune-inflammatory core of acute COVID-19 strongly predicts the development of physio-affective symptoms 3-4 months later, and these effects are partly mediated by neuro-immune and neuro-oxidative pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Hakeim</LastName><ForeName>Hussein Kadhem</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0001-6143-5196</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, College of Science, University of Kufa, Kufa 54002, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Rubaye</LastName><ForeName>Haneen Tahseen</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>College of Medical Laboratory Techniques, Imam Ja'afar Al-Sadiq University, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almulla</LastName><ForeName>Abbas F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-7667-6731</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Hadrawi</LastName><ForeName>Dhurgham Shihab</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Al-Najaf Center for Cardiac Surgery and Transcatheter Therapy, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC 3220, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidants</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neuro-immune</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest involving any commercial or other association connected with the submitted article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36675440</ArticleId><ArticleId IdType="pmc">PMC9865328</ArticleId><ArticleId IdType="doi">10.3390/jcm12020511</ArticleId><ArticleId IdType="pii">jcm12020511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Sachdeva R., Gower C., Ramsay M., Lopez Bernal J. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat. Med. 2022;28:831&#x2013;837. doi: 10.1038/s41591-022-01699-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01699-1</ArticleId><ArticleId IdType="pmc">PMC9018410</ArticleId><ArticleId IdType="pubmed">35045566</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas S.M., Vilches T.N., Zhang K., Wells C.R., Shoukat A., Singer B.H., Meyers L.A., Neuzil K.M., Langley J.M., Fitzpatrick M.C., et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin. Infect. Dis. 2021;73:2257&#x2013;2264. doi: 10.1093/cid/ciab079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab079</ArticleId><ArticleId IdType="pmc">PMC7929033</ArticleId><ArticleId IdType="pubmed">33515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A.M., Robinson D.A., Yang L., Williams C.F., Newman L.M., Breen J.J., Eisinger R.W., Schneider J.S., Adimora A.A., Erbelding E.J. Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19. Ann. Intern. Med. 2021;174:999&#x2013;1003. doi: 10.7326/M21-1043.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1043</ArticleId><ArticleId IdType="pmc">PMC8025940</ArticleId><ArticleId IdType="pubmed">33780290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Zhou F., Hou W., Silver Z., Wong C.Y., Chang O., Huang E., Zuo Q.K. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: A meta-analysis. Ann. N. Y. Acad. Sci. 2021;1486:90&#x2013;111. doi: 10.1111/nyas.14506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14506</ArticleId><ArticleId IdType="pmc">PMC7675607</ArticleId><ArticleId IdType="pubmed">33009668</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Florencio L.L. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int. J. Environ. Res. Public Health. 2021;18:2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., Noel A., Gunning S., Hatrick J., Hamilton S., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O., Lui L.M.W., Eskander S., Ceban F., Ho R., Di Vincenzo J.D., Rosenblat J.D., Lee Y., Subramaniapillai M., McIntyre R.S. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J. Psychiatr. Res. 2021;144:129&#x2013;137. doi: 10.1016/j.jpsychires.2021.09.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2021.09.054</ArticleId><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler C.X., Wyller V.B.B., Moss-Morris R., Buchwald D., Crawley E., Hautvast J., Katz B.Z., Knoop H., Little P., Taylor R., et al. Long COVID and Post-infective Fatigue Syndrome: A Review. Open Forum Infect. Dis. 2021;8:ofab440. doi: 10.1093/ofid/ofab440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab440</ArticleId><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K., Montenegro-Jim&#xe9;nez Y., Torres-Castro R., Vera-Uribe R., Torralba Y., Alsina-Restoy X., Vasconcello-Castillo L., Vilar&#xf3; J. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron. Respir. Dis. 2021;18:14799731211002240. doi: 10.1177/14799731211002240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14799731211002240</ArticleId><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J. Neurovirol. 2021;27:154&#x2013;159. doi: 10.1007/s13365-021-00949-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00949-1</ArticleId><ArticleId IdType="pmc">PMC7852482</ArticleId><ArticleId IdType="pubmed">33528827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M., Soddu D., Balbo P.E., Baricich A., Zeppegno P., Avanzi G.C., Baldon G., Bartolomei G., Battaglia M., Battistini S., et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw. Open. 2021;4:e2036142. doi: 10.1001/jamanetworkopen.2020.36142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36142</ArticleId><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Schiabor Barrett K.M., Riffle S., Bolze A., Neveux I., Dabe S., Grzymski J.J., Lu J.T., Washington N.L. Long-term COVID-19 symptoms in a large unselected population. medRxiv. 2010 doi: 10.1101/2020.10.07.20208702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.07.20208702</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Borst B., Peters J.B., Brink M., Schoon Y., Bleeker-Rovers C.P., Schers H., van Hees H.W.H., van Helvoort H., van den Boogaard M., van der Hoeven H., et al. Comprehensive Health Assessment 3 Months after Recovery from Acute Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2021;73:e1089&#x2013;e1098. doi: 10.1093/cid/ciaa1750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1750</ArticleId><ArticleId IdType="pmc">PMC7717214</ArticleId><ArticleId IdType="pubmed">33220049</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Tedesco Junior W.L.D., Lozovoy M.A.B., Mori M.T.E., Danelli T., Almeida E.R.D.d., Tejo A.M., Tano Z.N., Reiche E.M.V., Sim&#xe3;o A.N.C. In COVID-19, NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: A nomothetic network approach. Mol. Psychiatry. 2022;27:1945&#x2013;1955. doi: 10.1038/s41380-021-01431-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01431-4</ArticleId><ArticleId IdType="pmc">PMC8752583</ArticleId><ArticleId IdType="pubmed">35022530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcinkaya M., Liu W., Islam M.N., Kotini A.G., Gusarova G.A., Fidler T.P., Papapetrou E.P., Bhattacharya J., Wang N., Tall A.R. Modulation of the NLRP3 inflammasome by SARS-CoV-2 Envelope protein. Sci. Rep. 2021;11:24432. doi: 10.1038/s41598-021-04133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04133-7</ArticleId><ArticleId IdType="pmc">PMC8709866</ArticleId><ArticleId IdType="pubmed">34952919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N., Di B., Xu L.-L. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021;61:2&#x2013;15. doi: 10.1016/j.cytogfr.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8233448</ArticleId><ArticleId IdType="pubmed">34183243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagulkoo P., Plaimas K., Suratanee A., Colado Sim&#xe3;o A.N., Vissoci Reiche E.M., Maes M. Immunopathogenesis and Immunogenetic Variants in COVID-19. Curr. Pharm. Des. 2022;28:1780&#x2013;1797. doi: 10.2174/1381612828666220519150821.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612828666220519150821</ArticleId><ArticleId IdType="pubmed">35598232</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora S.M., Lieberman J., Wu H. Inflammasome activation at the crux of severe COVID-19. Nat. Rev. Immunol. 2021;21:694&#x2013;703. doi: 10.1038/s41577-021-00588-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00588-x</ArticleId><ArticleId IdType="pmc">PMC8351223</ArticleId><ArticleId IdType="pubmed">34373622</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C., Crespo &#xc3;.n., Ranjbar S., Lewandrowski M., Ingber J., de Lacerda L.B., Parry B., Ravid S., Clark S., Ho F., et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res. Sq. 2021:1&#x2013;42. doi: 10.21203/rs.3.rs-153628/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-153628/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues T.S., de S&#xe1; K.S.G., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gon&#xe7;alves A.V., Perucello D.B., Andrade W.A., Castro R., et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218:e20201707. doi: 10.1084/jem.20201707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K.V., Deng M., Ting J.P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477&#x2013;489. doi: 10.1038/s41577-019-0165-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0165-0</ArticleId><ArticleId IdType="pmc">PMC7807242</ArticleId><ArticleId IdType="pubmed">31036962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharakan S., Nomoto K., Miyashita S., Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. Crit. Care. 2020;24:298. doi: 10.1186/s13054-020-03045-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03045-8</ArticleId><ArticleId IdType="pmc">PMC7274509</ArticleId><ArticleId IdType="pubmed">32503659</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hadrawi D.S., Al-Rubaye H.T., Almulla A.F., Al-Hakeim H.K., Maes M. Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic approach. Acta Neuropsychiatr. 2022:1&#x2013;12. doi: 10.1017/neu.2022.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/neu.2022.21</ArticleId><ArticleId IdType="pubmed">36134517</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M. Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self. J. Pers. Med. 2022;12:403. doi: 10.3390/jpm12030403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12030403</ArticleId><ArticleId IdType="pmc">PMC8955533</ArticleId><ArticleId IdType="pubmed">35330403</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jassas H.K., Al-Hakeim H.K., Maes M. Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach. J. Affect. Disord. 2022;297:233&#x2013;245. doi: 10.1016/j.jad.2021.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.10.039</ArticleId><ArticleId IdType="pmc">PMC8541833</ArticleId><ArticleId IdType="pubmed">34699853</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Rubaye H.T., Al-Hadrawi D.S., Almulla A.F., Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: A proof of concept and mechanism study. Mol. Psychiatry. :2022. doi: 10.1038/s41380-022-01836-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01836-9</ArticleId><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Carvalho A.F. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. Mol. Neurobiol. 2018;55:8885&#x2013;8903. doi: 10.1007/s12035-018-1016-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1016-x</ArticleId><ArticleId IdType="pubmed">29611101</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Bonifacio K.L., Morelli N.R., Vargas H.O., Moreira E.G., St Stoyanov D., Barbosa D.S., Carvalho A.F., Nunes S.O.V. Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses. Neurotox. Res. 2018;34:489&#x2013;510. doi: 10.1007/s12640-018-9906-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-018-9906-2</ArticleId><ArticleId IdType="pubmed">29736827</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kubera M., Kota&#x144;ska M. Aberrations in the Cross-Talks Among Redox, Nuclear Factor-&#x3ba;B, and Wnt/&#x3b2;-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. Front. Psychiatry. 2022;13:822382. doi: 10.3389/fpsyt.2022.822382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.822382</ArticleId><ArticleId IdType="pmc">PMC9120845</ArticleId><ArticleId IdType="pubmed">35599774</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla F.A., Maes M. The Tryptophan Catabolite or Kynurenine Pathway&#x2019;s Role in Major Depression. Curr. Top. Med. Chem. 2022;22:1731&#x2013;1735. doi: 10.2174/1568026622666220428095250.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026622666220428095250</ArticleId><ArticleId IdType="pubmed">36321312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Fernando S.M., Pan A.Y., Laposa R., Cullen K.R., Klimes-Dougan B., Andreazza A.C. Characterizing the NLRP3 Inflammasome in Mood Disorders: Overview, Technical Development, and Measures of Peripheral Activation in Adolescent Patients. Int. J. Mol. Sci. 2021;22:12513. doi: 10.3390/ijms222212513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212513</ArticleId><ArticleId IdType="pmc">PMC8618969</ArticleId><ArticleId IdType="pubmed">34830395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann F.N., Costa A.P., Ghisleni G., Diaz A.P., Rodrigues A.L.S., Peluffo H., Kaster M.P. NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain Behav. Immun. 2017;64:367&#x2013;383. doi: 10.1016/j.bbi.2017.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.03.002</ArticleId><ArticleId IdType="pubmed">28263786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.T., Du X.M., Ma X.J., Zong Y., Chen J.K., Yu C.L., Liu Y.G., Chen Y.C., Zhao L.J., Lu G.C. Activation of the NLRP3 inflammasome in lipopolysaccharide-induced mouse fatigue and its relevance to chronic fatigue syndrome. J. Neuroinflamm. 2016;13:71. doi: 10.1186/s12974-016-0539-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0539-1</ArticleId><ArticleId IdType="pmc">PMC4822300</ArticleId><ArticleId IdType="pubmed">27048470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Ma X., Xia Z., Chen J., Liu Y., Chen Y., Zhu J., Li J., Yu H., Zong Y., et al. NLRP3 inflammasome activation mediates fatigue-like behaviors in mice via neuroinflammation. Neuroscience. 2017;358:115&#x2013;123. doi: 10.1016/j.neuroscience.2017.06.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.06.048</ArticleId><ArticleId IdType="pubmed">28684277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwar R., Rolfe A., Di L., Blevins H., Xu Y., Sun X., Bloom G.S., Zhang S., Sun D. A Novel Inhibitor Targeting NLRP3 Inflammasome Reduces Neuropathology and Improves Cognitive Function in Alzheimer&#x2019;s Disease Transgenic Mice. J. Alzheimers Dis. 2021;82:1769&#x2013;1783. doi: 10.3233/JAD-210400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210400</ArticleId><ArticleId IdType="pmc">PMC8384725</ArticleId><ArticleId IdType="pubmed">34219728</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C., Trageser K.J., Wu H., Herman F.J., Iqbal U.H., Sebastian-Valverde M., Frolinger T., Zeng E., Pasinetti G.M. Anxiolytic effects of NLRP3 inflammasome inhibition in a model of chronic sleep deprivation. Transl. Psychiatry. 2021;11:52. doi: 10.1038/s41398-020-01189-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01189-3</ArticleId><ArticleId IdType="pmc">PMC7809257</ArticleId><ArticleId IdType="pubmed">33446652</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghaie F., Moradifar F., Hosseini A. Rapamycin attenuates depression and anxiety-like behaviors through modulation of the NLRP3 pathway in pentylenetetrazole-kindled male Wistar rats. Fundam. Clin. Pharmacol. 2021;35:1045&#x2013;1054. doi: 10.1111/fcp.12689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/fcp.12689</ArticleId><ArticleId IdType="pubmed">33930202</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M.H., Stoyanov D. False dogmas in mood disorders research: Towards a nomothetic network approach. World J. Psychiatry. 2022;12:651&#x2013;667. doi: 10.5498/wjp.v12.i5.651.</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v12.i5.651</ArticleId><ArticleId IdType="pmc">PMC9150032</ArticleId><ArticleId IdType="pubmed">35663296</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021. WHO; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Morris G., Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013;11:205. doi: 10.1186/1741-7015-11-205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-205</ArticleId><ArticleId IdType="pmc">PMC3847236</ArticleId><ArticleId IdType="pubmed">24229326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachrisson O., Regland B., Jahreskog M., Kron M., Gottfries C.G. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale) J. Psychosom. Res. 2002;52:501&#x2013;509. doi: 10.1016/S0022-3999(01)00315-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(01)00315-4</ArticleId><ArticleId IdType="pubmed">12069875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J. Neurol. Neurosurg Psychiatry. 1960;23:56&#x2013;62. doi: 10.1136/jnnp.23.1.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.23.1.56</ArticleId><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck A.T., Steer R.A., Brown G. APA PsycTests. American Psychological Association; Washington, DC, USA: Beck Depression Inventory&#x2013;II (BDI-II) [Database Record] p. 1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/t00742-000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50&#x2013;55. doi: 10.1111/j.2044-8341.1959.tb00467.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8341.1959.tb00467.x</ArticleId><ArticleId IdType="pubmed">13638508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Xu L., Lv W., Han L., Xiang Y., Fu L., Jin M., Zhou R., Chen H., Zhang A. An NLRP3 inflammasome-triggered cytokine storm contributes to Streptococcal toxic shock-like syndrome (STSLS) PLoS Pathog. 2019;15:e1007795. doi: 10.1371/journal.ppat.1007795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007795</ArticleId><ArticleId IdType="pmc">PMC6553798</ArticleId><ArticleId IdType="pubmed">31170267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik Jennifer R., Korth Marcus J., Simmons Cameron P., Farrar J., Martin Thomas R., Katze Michael G. Into the Eye of the Cytokine Storm. Microbiol. Mol. Biol. Rev. 2012;76:16&#x2013;32. doi: 10.1128/MMBR.05015-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.X., Zheng H.L., Luo Y., He J.G., Wang W., Han J., Zhang L., Wang X., Ni L., Zhou H.Y., et al. Gene deficiency and pharmacological inhibition of caspase-1 confers resilience to chronic social defeat stress via regulating the stability of surface AMPARs. Mol. Psychiatry. 2018;23:556&#x2013;568. doi: 10.1038/mp.2017.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.76</ArticleId><ArticleId IdType="pmc">PMC5822452</ArticleId><ArticleId IdType="pubmed">28416811</ArticleId></ArticleIdList></Reference><Reference><Citation>Towers A.E., Oelschlager M.L., Patel J., Gainey S.J., McCusker R.H., Freund G.G. Acute fasting inhibits central caspase-1 activity reducing anxiety-like behavior and increasing novel object and object location recognition. Metabolism. 2017;71:70&#x2013;82. doi: 10.1016/j.metabol.2017.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2017.03.005</ArticleId><ArticleId IdType="pmc">PMC5439304</ArticleId><ArticleId IdType="pubmed">28521881</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartz J.R., Prather A.A., Di Iorio C.R., Bogdan R., Hariri A.R. A Functional Interleukin-18 Haplotype Predicts Depression and Anxiety through Increased Threat-Related Amygdala Reactivity in Women but Not Men. Neuropsychopharmacology. 2017;42:419&#x2013;426. doi: 10.1038/npp.2016.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2016.129</ArticleId><ArticleId IdType="pmc">PMC5399226</ArticleId><ArticleId IdType="pubmed">27430614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardcastle S.L., Brenu E.W., Johnston S., Nguyen T., Huth T., Ramos S., Staines D., Marshall-Gradisnik S. Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients. Int. J. Med. Sci. 2015;12:764&#x2013;772. doi: 10.7150/ijms.12399.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.12399</ArticleId><ArticleId IdType="pmc">PMC4615236</ArticleId><ArticleId IdType="pubmed">26516304</ArticleId></ArticleIdList></Reference><Reference><Citation>VanElzakker M.B., Brumfield S.A., Lara Mejia P.S. Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods. Front. Neurol. 2019;9:1033. doi: 10.3389/fneur.2018.01033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01033</ArticleId><ArticleId IdType="pmc">PMC6335565</ArticleId><ArticleId IdType="pubmed">30687207</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L., Pei L., Yao S., Wu Y., Shang Y. NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies. Front. Cell. Neurosci. 2017;11:63. doi: 10.3389/fncel.2017.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00063</ArticleId><ArticleId IdType="pmc">PMC5343070</ArticleId><ArticleId IdType="pubmed">28337127</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon J.G. Inflammatory Cytokines in Nonpathological States. News Physiol Sci. 2000;15:298&#x2013;303. doi: 10.1152/physiologyonline.2000.15.6.298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiologyonline.2000.15.6.298</ArticleId><ArticleId IdType="pubmed">11390930</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez J.I., Dodelet-Devillers A., Kebir H., Ifergan I., Fabre P.J., Terouz S., Sabbagh M., Wosik K., Bourbonni&#xe8;re L., Bernard M., et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334:1727&#x2013;1731. doi: 10.1126/science.1206936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1206936</ArticleId><ArticleId IdType="pubmed">22144466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari C.C., Depino A.M., Prada F., Muraro N., Campbell S., Podhajcer O., Perry V.H., Anthony D.C., Pitossi F.J. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am. J. Pathol. 2004;165:1827&#x2013;1837. doi: 10.1016/S0002-9440(10)63438-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63438-4</ArticleId><ArticleId IdType="pmc">PMC1618664</ArticleId><ArticleId IdType="pubmed">15509551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahira M., Ahn H.J., Park W.R., Gao P., Tomura M., Park C.S., Hamaoka T., Ohta T., Kurimoto M., Fujiwara H. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J. Immunol. 2002;168:1146&#x2013;1153. doi: 10.4049/jimmunol.168.3.1146.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.3.1146</ArticleId><ArticleId IdType="pubmed">11801649</ArticleId></ArticleIdList></Reference><Reference><Citation>Boss&#xf9; P., Ciaramella A., Salani F., Vanni D., Palladino I., Caltagirone C., Scapigliati G. Interleukin-18, from neuroinflammation to Alzheimer&#x2019;s disease. Curr. Pharm. Des. 2010;16:4213&#x2013;4224. doi: 10.2174/138161210794519147.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210794519147</ArticleId><ArticleId IdType="pubmed">21184660</ArticleId></ArticleIdList></Reference><Reference><Citation>Felderhoff-Mueser U., Schmidt O.I., Oberholzer A., B&#xfc;hrer C., Stahel P.F. IL-18: A key player in neuroinflammation and neurodegeneration? Trends Neurosci. 2005;28:487&#x2013;493. doi: 10.1016/j.tins.2005.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2005.06.008</ArticleId><ArticleId IdType="pubmed">16023742</ArticleId></ArticleIdList></Reference><Reference><Citation>Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer&#x2019;s disease: Peripheral inflammation or signals from the brain? J. Neuroimmunol. 2000;103:97&#x2013;102. doi: 10.1016/S0165-5728(99)00226-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(99)00226-X</ArticleId><ArticleId IdType="pubmed">10674995</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong B.A., Huizinga T.W., Bollen E.L., Uitdehaag B.M., Bosma G.P., van Buchem M.A., Remarque E.J., Burgmans A.C., Kalkers N.F., Polman C.H., et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J. Neuroimmunol. 2002;126:172&#x2013;179. doi: 10.1016/S0165-5728(02)00056-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00056-5</ArticleId><ArticleId IdType="pubmed">12020968</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W.X., Huang P., Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult. Scler. J. 2004;10:482&#x2013;487. doi: 10.1191/1352458504ms1071oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/1352458504ms1071oa</ArticleId><ArticleId IdType="pubmed">15471361</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brown J.S., Denneny E.K., Hare S.S., Heightman M., Hillman T.E., Jacob J., Jarvis H.C., et al. &#x2018;Long-COVID&#x2019;: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gameil M.A., Marzouk R.E., Elsebaie A.H., Rozaik S.E. Long-term clinical and biochemical residue after COVID-19 recovery. Egypt. Liver J. 2021;11:74. doi: 10.1186/s43066-021-00144-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43066-021-00144-1</ArticleId><ArticleId IdType="pmc">PMC8435147</ArticleId><ArticleId IdType="pubmed">34777873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuta A.E., Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 1986;164:321&#x2013;326. doi: 10.1084/jem.164.1.321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.164.1.321</ArticleId><ArticleId IdType="pmc">PMC2188195</ArticleId><ArticleId IdType="pubmed">3723078</ArticleId></ArticleIdList></Reference><Reference><Citation>Song I.U., Kim J.S., Chung S.W., Lee K.S. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson&#x2019;s disease? A comparison of Parkinson&#x2019;s disease patients, disease controls and healthy individuals. Eur. Neurol. 2009;62:99&#x2013;104. doi: 10.1159/000222780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000222780</ArticleId><ArticleId IdType="pubmed">19521085</ArticleId></ArticleIdList></Reference><Reference><Citation>Windgassen E.B., Funtowicz L., Lunsford T.N., Harris L.A., Mulvagh S.L. C-reactive protein and high-sensitivity C-reactive protein: An update for clinicians. Postgrad. Med. 2011;123:114&#x2013;119. doi: 10.3810/pgm.2011.01.2252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2011.01.2252</ArticleId><ArticleId IdType="pubmed">21293091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsuchou H., Kastin A.J., Mishra P.K., Pan W. C-reactive protein increases BBB permeability: Implications for obesity and neuroinflammation. Cell. Physiol. Biochem. 2012;30:1109&#x2013;1119. doi: 10.1159/000343302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343302</ArticleId><ArticleId IdType="pmc">PMC4099000</ArticleId><ArticleId IdType="pubmed">23018453</ArticleId></ArticleIdList></Reference><Reference><Citation>Belin C., Devic P., Ayrignac X., Dos Santos A., Paix A., Sirven-Villaros L., Simard C., Lamure S., Gastinne T., Ursu R., et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci. Rep. 2020;10:18997. doi: 10.1038/s41598-020-76055-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76055-9</ArticleId><ArticleId IdType="pmc">PMC7642402</ArticleId><ArticleId IdType="pubmed">33149178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X., Xu X.-y., Feng C.-h., Wang Y., Li Y.-l., Feng B. Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. BMC Neurol. 2013;13:110. doi: 10.1186/1471-2377-13-110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-110</ArticleId><ArticleId IdType="pmc">PMC3765839</ArticleId><ArticleId IdType="pubmed">23978069</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkind M.S., Tai W., Coates K., Paik M.C., Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern. Med. 2006;166:2073&#x2013;2080. doi: 10.1001/archinte.166.19.2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.19.2073</ArticleId><ArticleId IdType="pubmed">17060536</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Napoli M., Papa F., Bocola V. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke. 2001;32:917&#x2013;924. doi: 10.1161/01.STR.32.4.917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.32.4.917</ArticleId><ArticleId IdType="pubmed">11283392</ArticleId></ArticleIdList></Reference><Reference><Citation>Masotti L., Ceccarelli E., Forconi S., Cappelli R. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J. Intern. Med. 2005;258:145&#x2013;152. doi: 10.1111/j.1365-2796.2005.01514.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2005.01514.x</ArticleId><ArticleId IdType="pubmed">16018791</ArticleId></ArticleIdList></Reference><Reference><Citation>Montaner J., Fernandez-Cadenas I., Molina C.A., Rib&#xf3; M., Huertas R., Rosell A., Penalba A., Ortega L., Chac&#xf3;n P., Alvarez-Sab&#xed;n J. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke. 2006;37:1205&#x2013;1210. doi: 10.1161/01.STR.0000217744.89208.4e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000217744.89208.4e</ArticleId><ArticleId IdType="pubmed">16601211</ArticleId></ArticleIdList></Reference><Reference><Citation>Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom. Med. 2009;71:171&#x2013;186. doi: 10.1097/PSY.0b013e3181907c1b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0b013e3181907c1b</ArticleId><ArticleId IdType="pubmed">19188531</ArticleId></ArticleIdList></Reference><Reference><Citation>Roomruangwong C., Kanchanatawan B., Sirivichayakul S., Mahieu B., Nowak G., Maes M. Lower Serum Zinc and Higher CRP Strongly Predict Prenatal Depression and Physio-somatic Symptoms, Which All Together Predict Postnatal Depressive Symptoms. Mol. Neurobiol. 2017;54:1500&#x2013;1512. doi: 10.1007/s12035-016-9741-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9741-5</ArticleId><ArticleId IdType="pubmed">26846364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasupanrajit A., Jirakran K., Tunvirachaisakul C., Solmi M., Maes M. Inflammation and nitro-oxidative stress in current suicidal attempts and current suicidal ideation: A systematic review and meta-analysis. Mol. Psychiatry. 2022;27:1350&#x2013;1361. doi: 10.1038/s41380-021-01407-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01407-4</ArticleId><ArticleId IdType="pubmed">34997194</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello H., Gould R.L., Abrol E., Howard R. Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. BMJ Open. 2019;9:e027925. doi: 10.1136/bmjopen-2018-027925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-027925</ArticleId><ArticleId IdType="pmc">PMC6661660</ArticleId><ArticleId IdType="pubmed">31326932</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge R., Sartor M.L., Scott F., Cleare A.J. Inflammatory proteins are altered in chronic fatigue syndrome-A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2019;107:69&#x2013;83. doi: 10.1016/j.neubiorev.2019.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.08.011</ArticleId><ArticleId IdType="pubmed">31465778</ArticleId></ArticleIdList></Reference><Reference><Citation>Arce Renter&#xed;a M., Gillett S.R., McClure L.A., Wadley V.G., Glasser S.P., Howard V.J., Kissela B.M., Unverzagt F.W., Jenny N.S., Manly J.J., et al. C-reactive protein and risk of cognitive decline: The REGARDS study. PLoS ONE. 2020;15:e0244612. doi: 10.1371/journal.pone.0244612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244612</ArticleId><ArticleId IdType="pmc">PMC7774911</ArticleId><ArticleId IdType="pubmed">33382815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathy-Hartert M., Bourgeois E., Gr&#xfc;lke S., Deby-Dupont G., Caudron I., Deby C., Lamy M., Serteyn D. Purification of myeloperoxidase from equine polymorphonuclear leucocytes. Can. J. Vet. Res. 1998;62:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189459</ArticleId><ArticleId IdType="pubmed">9553712</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz Nizer W.S., Inkovskiy V., Overhage J. Surviving Reactive Chlorine Stress: Responses of Gram-Negative Bacteria to Hypochlorous Acid. Microorganisms. 2020;8:1220. doi: 10.3390/microorganisms8081220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8081220</ArticleId><ArticleId IdType="pmc">PMC7464077</ArticleId><ArticleId IdType="pubmed">32796669</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Landucci Bonifacio K., Morelli N.R., Vargas H.O., Barbosa D.S., Carvalho A.F., Nunes S.O.V. Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder. Mol. Neurobiol. 2019;56:141&#x2013;156. doi: 10.1007/s12035-018-1051-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1051-7</ArticleId><ArticleId IdType="pubmed">29681025</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E., Thomas T.L., Betmouni S., Scolding N., Love S. Elevated Activity and Microglial Expression of Myeloperoxidase in Demyelinated Cerebral Cortex in Multiple Sclerosis. Brain Pathol. 2008;18:86&#x2013;95. doi: 10.1111/j.1750-3639.2007.00110.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2007.00110.x</ArticleId><ArticleId IdType="pmc">PMC8095620</ArticleId><ArticleId IdType="pubmed">18042261</ArticleId></ArticleIdList></Reference><Reference><Citation>Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., Heinecke J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer&#x2019;s disease. J. Neurochem. 2004;90:724&#x2013;733. doi: 10.1111/j.1471-4159.2004.02527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02527.x</ArticleId><ArticleId IdType="pubmed">15255951</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccarino V., Brennan M.-L., Miller A.H., Bremner J.D., Ritchie J.C., Lindau F., Veledar E., Su S., Murrah N.V., Jones L., et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: A twin study. Biol. Psychiatry. 2008;64:476&#x2013;483. doi: 10.1016/j.biopsych.2008.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2008.04.023</ArticleId><ArticleId IdType="pmc">PMC2597204</ArticleId><ArticleId IdType="pubmed">18514165</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S., Li X., Huang W., Gong H. Change of serum myeloperoxidase and lipoxin A4 level in coronary heart disease patients with anxiety and/or depression. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013;38:370&#x2013;375. doi: 10.3969/j.issn.1672-7347.2013.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1672-7347.2013.04.006</ArticleId><ArticleId IdType="pubmed">23645243</ArticleId></ArticleIdList></Reference><Reference><Citation>Talarowska M., Szemraj J., Ga&#x142;ecki P. Myeloperoxidase gene expression and cognitive functions in depression. Adv. Med. Sci. 2015;60:1&#x2013;5. doi: 10.1016/j.advms.2014.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2014.06.001</ArticleId><ArticleId IdType="pubmed">25038328</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava S., Chelluboina S., Jedge P., Doke P., Palkar S., Mishra A.C., Arankalle V.A. Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated with Disease Severity in COVID-19 Patients. Front. Cell. Infect. Microbiol. 2021;11:1056. doi: 10.3389/fcimb.2021.751232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.751232</ArticleId><ArticleId IdType="pmc">PMC8566808</ArticleId><ArticleId IdType="pubmed">34746027</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M.R., Islam M.R., Shalahuddin Qusar M.M.A., Islam M.S., Kabir M.H., Mustafizur Rahman G.K.M., Islam M.S., Hasnat A. Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: A case-control study. BMC Psychiatry. 2018;18:94. doi: 10.1186/s12888-018-1685-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-018-1685-z</ArticleId><ArticleId IdType="pmc">PMC5891975</ArticleId><ArticleId IdType="pubmed">29631563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden C.L., Huang L.G., Javors M.A., Johnson J.M., Seleshi E., McIntyre K., Contreras S., Maas J.W. Calcium function in affective disorders and healthy controls. Biol. Psychiatry. 1988;23:367&#x2013;376. doi: 10.1016/0006-3223(88)90287-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-3223(88)90287-9</ArticleId><ArticleId IdType="pubmed">2963665</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dujaili A.H., Al-Hakeim H.K., Twayej A.J., Maes M. Total and ionized calcium and magnesium are significantly lowered in drug-na&#xef;ve depressed patients: Effects of antidepressants and associations with immune activation. Metab. Brain Dis. 2019;34:1493&#x2013;1503. doi: 10.1007/s11011-019-00458-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-019-00458-5</ArticleId><ArticleId IdType="pubmed">31292851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K.I., Ock S.M., Chung J.H., Song C.H. Associations of serum Ca and Mg levels with mental health in adult women without psychiatric disorders. Biol. Trace Elem. Res. 2010;133:153&#x2013;161. doi: 10.1007/s12011-009-8421-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-009-8421-y</ArticleId><ArticleId IdType="pubmed">19543697</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul I.A. Antidepressant activity and calcium signaling cascades. Hum. Psychopharmacol. 2001;16:71&#x2013;80. doi: 10.1002/hup.186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hup.186</ArticleId><ArticleId IdType="pubmed">12404601</ArticleId></ArticleIdList></Reference><Reference><Citation>Toescu E.C., Verkhratsky A. The importance of being subtle: Small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell. 2007;6:267&#x2013;273. doi: 10.1111/j.1474-9726.2007.00296.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2007.00296.x</ArticleId><ArticleId IdType="pubmed">17517038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst K. Primary hyperparathyroidism as a secondary cause of depression. J. Am. Board Fam. Med. 2010;23:677&#x2013;680. doi: 10.3122/jabfm.2010.05.090199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2010.05.090199</ArticleId><ArticleId IdType="pubmed">20823364</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;tzner T.M., Listunova L., Fabian G.A., Kramer B.A., Flach D., Weisbrod M., Roesch-Ely D., Sharma A. Serum calcium levels and neuropsychological performance in depression and matched healthy controls: Reversal of correlation a marker of the aging cognitive clock? Psychoneuroendocrinology. 2018;91:198&#x2013;205. doi: 10.1016/j.psyneuen.2018.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2018.03.012</ArticleId><ArticleId IdType="pubmed">29587243</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla A.F., Thipakorn Y., Vasupanrajit A., Abo Algon A.A., Tunvirachaisakul C., Hashim Aljanabi A.A., Ox-enkrug G., Al-Hakeim H.K., Maes M. The tryptophan catabolite or kynurenine pathway in major depressive and bi-polar disorder: A systematic review and meta-analysis. Brain Behav. Immun. Health. 2022;26:100537. doi: 10.1016/j.bbih.2022.100537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100537</ArticleId><ArticleId IdType="pmc">PMC9630622</ArticleId><ArticleId IdType="pubmed">36339964</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new &#x2018;5-HT&#x2019; hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011;35:702&#x2013;721. doi: 10.1016/j.pnpbp.2010.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2010.12.017</ArticleId><ArticleId IdType="pubmed">21185346</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Song C., Lin A.H., Bonaccorso S., Kenis G., De Jongh R., Bosmans E., Scharp&#xe9; S. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20:370&#x2013;379. doi: 10.1016/S0893-133X(98)00088-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0893-133X(98)00088-8</ArticleId><ArticleId IdType="pubmed">10088138</ArticleId></ArticleIdList></Reference><Reference><Citation>Seneff S., Nigh G., Kyriakopoulos A.M., McCullough P.A. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem. Toxicol. 2022;164:113008. doi: 10.1016/j.fct.2022.113008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2022.113008</ArticleId><ArticleId IdType="pmc">PMC9012513</ArticleId><ArticleId IdType="pubmed">35436552</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J., Vogel G. Vaccines may cause rare, Long COVID-like symptoms. Science. 2022;375:364&#x2013;366. doi: 10.1126/science.ada0536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ada0536</ArticleId><ArticleId IdType="pubmed">35084966</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M. Different SARS-CoV-2 variants may give rise to different long COVID symptoms, study suggests; Proceedings of the European Congress of Clinical Microbiology &amp; Infectious Diseases (ECCMID 2022); Lisbon, Portugal. 23&#x2013;26 April 2022.</Citation></Reference><Reference><Citation>Al-Rashedi N.A.M., Alburkat H., Hadi A.O., Munahi M.G., Jasim A., Hameed A., Oda B.S., Lilo K.M., AlObaidi L.A.H., Vapalahti O., et al. High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020&#x2013;2021. PLoS ONE. 2022;17:e0267295. doi: 10.1371/journal.pone.0267295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267295</ArticleId><ArticleId IdType="pmc">PMC9135184</ArticleId><ArticleId IdType="pubmed">35617193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaxia  Iraq Reports First Cases of COVID-19 Omicron Variant.  [(accessed on 13 October 2022)].  Available online:  https://english.news.cn/20220106/e6eedae158c44eea8433caf983a10738/c.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>